Trial ID 20423 | Maryland Oncology Hematology Trial ID 20423 – Maryland Oncology Hematology

Trial ID 20423

Trial Information - Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

Disease Specifics: (NSCLC)

Protocol ID: eFT508-0011

Sponsor: eFFECTOR Therapeutics

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lung

Investigator

Narang MD, Mohit

Status

OPEN TO ENROLLMENT

Sponsor

eFFECTOR Therapeutics

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology